MTSL Issue 1039
MTSL Issue 1039 (dated 11/21/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #ESPR #esperion #MDGL #madrigal #SGMO #sangamo #VXRT #vaxart #VKTX #vikingtherapeutics
MTSL Issue 1038
MTSL Issue 1038 (dated 11/07/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #CLDX #celldex #ESPR #esperion #MDGL #madrigal #VKTX #viking
Viking Therapeutics (VKTX) – Oral ‘2735 Looks Great With 6.8% Weight Loss
BIOINVEST BREAKING NEWS – Viking (VKTX) presented excellent updates for both high dose oral and subQ VK2735 at Obesity Week. The data continues to demonstrate best in class potential for the leading 2nd generation oral/subQ GLP-1/GIP program. (…more)
MTSL Issue 1037
MTSL Issue 1037 (dated 10/24/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycletherapeutics #SGMO #sangamo #VKTX #viking
MTSL Issue 1036
MTSL Issue 1036 (dated 10/10/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #ESPR #esperion #IONS #ionis #VXRT #vaxart #VKTX #viking
MTSL Issue 1031
MTSL Issue 1031 (dated 07/25/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BCYC #bicycle #IONS #ionis #SGMO #sangamo #SKYE #VKTX #viking
Viking Therapeutics (VKTX) – VK2735 subQ Moving into Phase III & Oral Phase II by Year End As VK2735 Continues Emergence as Best-in-Class GLP
BIOINVEST BREAKING NEWS – Viking (VKTX) held an excellent Q2:24 call with important positive clinical and regulatory updates for both VK2735 subQ and oral. BUY. (…more)
MTSL Issue 1029
MTSL Issue 1029 (dated 06/27/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #esperion #VKTX #viking
MTSL Issue 1028
MTSL Issue 1028 (dated 06/13/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #MDGL #madrigal #PGEN #preceign #SKYE #VXRT #vaxart #VKTX #viking
Viking Therapeutics (VKTX) – VKTX Down on Positive VK2809 NASH Data
BIOINVEST BREAKING NEWS – Viking Therapeutics (VKTX) – VKTX is trading down after the release of positive 52 week histology data for VK2809 in NASH. In our view, overall investor concerns around timing and likelihood of partnerships for VKTX in the large Obesity and NASH markets are driving the stock down with today’s move a “sell the news” event. (…more)
MTSL Issue 1025
MTSL Issue 1025 (dated 04/25/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycle #CLDX #celldex #INCY #incyte #MDGL #madrigal #PGEN #precigen #VKTX #viking
MTSL Issue 1023
MTSL Issue 1023 (dated 03/28/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #esperion #SGMO #sangamo #VXRT #vaxart #VKTX #viking
Viking Therapeutics (VKTX) – Oral VK2735 Delivers Excellent Phase I Weight Loss of 5.3% at 28 Days; Highest Dose Not Reached Yet Due to Outstanding Safety
BIOINVEST BREAKING NEWS – Viking (VKTX) Viking Therapeutics (VKTX) – Oral VK2735 Delivers Excellent Phase I Weight Loss of 5.3% at 28 Days; Highest Dose Not Reached Yet Due to Outstanding Safety. (…more)
MTSL Issue 1022
MTSL Issue 1022 (dated 03/14/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #INCY #incyte #MDGL #madrigal #SGMO #sangamo #SKYE #VKTX #viking
MTSL Issue 1021
MTSL Issue 1021 (dated 02/29/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #BMRN #biomarin #CLDX #celldex #ESPR #esperion #SKYE #skye #VKTX #viking
MTSL Issue 1020
MTSL Issue 1020 (dated 02/15/24) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #MDGL #madrigal #SGMO #sangamo #VKTX #viking
Madrigal (MDGL) & Viking Therapeutics (VKTX) – LLY’s Phase II MASH Data Puts Pressure on MDGL (March 14 PDUFA) & VKTX (Q1 Phase I Oral Data)
BIOINVEST BREAKING NEWS – Viking (VKTX) Viking Therapeutics (VKTX) – LLY’s Phase II MASH Data Puts Pressure on MDGL (March 14 PDUFA) & VKTX (Q1 Phase I Oral Data), Both Still BUYS With Upcoming Catalysts (…more)
MTSL Issue 1016
MTSL Issue 1016 (dated 12/14/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #acadia #ESPR #esperion #INCY #incyte #VKTX #viking
Viking Therapeutics (VKTX) – Significantly Undervalued After Roche Pays $2.7 Billion For Competitor
BIOINVEST BREAKING NEWS – Viking (VKTX) Viking Therapeutics (VKTX) – Significantly Undervalued After Roche Pays $2.7 Billion For Competitor, Phase I ‘2735 Oral Proof-of-Concept Data in Q1 2024. (…more)
MTSL Issue 1014
MTSL Issue 1014 (dated 11/16/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #CLDX #celldex #ESPR #esperion #MDGL #madrigal #PGEN #precigen #VKTX #viking
MTSL Issue 1012
MTSL Issue 1012 (dated 10/19/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #ionis #INCY #incyte #VKTX #viking
MTSL Issue 1011
MTSL Issue 1011 (dated 09/28/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycle #CLDX #celldex #IONS #ionis #VKTX #viking
MTSL Issue 1010
MTSL Issue 1010 (dated 09/14/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycle #BMRN #biomarin #MDGL #madrigal #VXRT #vaxart #VKTX #viking
MTSL Issue 1007
MTSL Issue 1007 (dated 08/03/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermesg #ESPR #esperion #INCY #incyte #PCRX #pacira #THRN #thorne #VKTX #viking
MTSL Issue 1005
MTSL Issue 1005 (dated 07/06/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #esperion #INCY #incyte #MDGL #madrigal #VKTX #viking #VXRT #vaxart
Madrigal (MDGL) — MDGL/VKTX Strong BUYs After Overreaction to Lilly Phase II Data
Madrigal (MDGL) / Viking (VKTX) are both strong BUYS after the overreaction to Lilly’s Phase II, 337 patients, data that showed a 24% weight loss at 48 weeks in the high dose from their new triple drug combo.Madrigal (MDGL) / Viking (VKTX) Strong BUYs After Overreaction to Lilly Phase II Data (…more)
MTSL Issue 1002
MTSL Issue 1002 (dated 5/25/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #SGMO #sangamo #VKTX #viking
Viking (VKTX) — VKTX Delivers Excellent Phase IIb VOYAGER Data in NASH
BIOINVEST BREAKING NEWS – Viking (VKTX) delivered the goods this morning when they announced positive top-line results from its Phase IIb VOYAGER clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). (…more)
MTSL Issue 1000
MTSL Issue 1000 (dated 4/27/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #BMRN #biomarin #MDGL #madrigal #PGEN #precigen #SGMO #sangamo #VKTX #viking
MTSL Issue 998
MTSL Issue 998 (dated 3/30/23) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BCYC #bicycle #CLDX #celldex #INCY #incyte #IONS #ionis #MYOV #myovant #SGMO #sangamo #VKTX #viking #ZYNE #zynerba